Detection of Cellular Receptors Specific for the Hepatitis B Virus preS Surface Protein on Cell Lines of Extrahepatic Origin

Park, Jung Hyun; Choi, Eun A; Cho, Eun Wie; Lee, Yun Jung; Park, Jung Min; Na, Shin Young; Kim, Kil Lyong

doi:10.1006/bbrc.2000.3661

Cited by 6 publications

(4 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, in serving as a cellular receptor for hepatothropic viruses such as HBV, liver-specific expression of ASGPR was as expected. Nevertheless, extra-hepatic detection of replicating HBV suggested the binding and internalization of HBV also into other cell types (Ilan et al 1996;Park et al 2000;Pontisso et al 1991), which implicated either the involvement of a second type of virus receptor in these cells or the extra-hepatic expression of the ASPGR in these cells. Neither has been definitively proven so far, but some earlier reports on extra-hepatic expression of ASGPR led us to consider the latter possibility.…”

Section: Discussionmentioning

confidence: 99%

Detection of surface asialoglycoprotein receptor expression in hepatic and extra-hepatic cells using a novel monoclonal antibody

2006

Self Cite

View full text Add to dashboard Cite

The asialoglycoprotein receptor (ASGPR) is a heterodimeric membrane protein which is involved in the internalization of desialylated glycoproteins and also in the binding and uptake of various pathogenic viruses. To facilitate the analysis of ASGPR expression, we generated a monoclonal antibody, termed ASSA-1, that is specific to the ASGPR H1 subunit based on ELISA and Western blots analysis. ASSA-1 also reacted to surface-displayed ASGPR in live cells thus enabling analysis of ASGPR expression by immunofluorescence flow cytometry, which we used to analyze established human liver cell lines previously confirmed to be positive for ASGPR mRNA expression. In agreement with previous reports, surface ASGPR was also detected in extra-hepatic cells and, surprisingly, even in human T cell lines, which was then further confirmed in activated, but not in resting, primary human peripheral blood lymphocytes. These observations suggest that ASGPR has a broad pattern of expression that even extends into cells from the immune system, which biological meanings still have to be analyzed. We expect that monoclonal antibody ASSA-1 will serve as a new powerful tool in analyzing the biological role of ASGPR in hepatic and extra-hepatic cells.

show abstract

Section: Discussionmentioning

confidence: 99%

Detection of surface asialoglycoprotein receptor expression in hepatic and extra-hepatic cells using a novel monoclonal antibody

2006

Self Cite

View full text Add to dashboard Cite

show abstract

“…Compared with viral particles or full-length L proteins, the smaller preS1 peptide was considered to be better exposed, easier for modification, and might have lower non-specific binding. Of note, previous studies have tried to use preS1 peptide or preS1 fusion proteins as bait but have failed to identify any functional HBV receptor through conventional immunoprecipitation (IP) methods [ 13 , 18 , 20 , 23 ]. Except for using the improper cells for receptor identification, the following possibilities may also have contributed to the failure of many previous attempts for receptor hunting.…”

Section: Bait and Hookmentioning

confidence: 99%

“…Many studies interested in the HBV receptor identified preS1 interacting proteins and considered them as putative HBV receptors. The incomplete list includes interleukin-6 (IL6) [ 12 ], human squamous cell carcinoma antigen 1(SCCA1) [ 13 ], the immunoglobulin A receptor (IgA R) [ 14 ], asialoglycoprotein receptor (ASGPR) [ 15 ], glyceraldehyde 3 phosphate dehydrogenase (GAPDH) [ 16 ], nascent polypeptide-associated complex a polypeptide (NACA) [ 17 ], glucose-regulated proteins (GRP75) [ 18 ], lipoprotein lipase [ 19 ], and four PreS1 binding proteins with an unknown identity and apparent molecular weight of 30 kDa [ 20 ], 47 kDa (HBV-BP) [ 21 ], 50 kDa (HBV-BF) [ 22 ], and 80 kDa (P80) [ 23 ], respectively. However, none of the proposed putative receptors can confer susceptibility to non-permissive cells through exogenous expression, and none of these studies further investigated the post-binding events mediated by these proteins.…”

Section: Introductionmentioning

confidence: 99%

Key Factors for “Fishing” NTCP as a Functional Receptor for HBV and HDV

Yan

Wang

2023

Viruses

View full text Add to dashboard Cite

About ten years ago, Wenhui Li’s research group in China identified the sodium taurocholate co-transporting polypeptide (NTCP), a bile acid transporter predominantly expressed in the liver, as a functional receptor for hepatitis B virus (HBV) and its satellite hepatitis delta virus (HDV) through biochemical and genetic studies. This finding unraveled a longtime mystery in the HBV field and led to the establishment of efficient and easy-to-use HBV infection models, which paved the way for the in-depth study of the HBV entry mechanism and facilitated the development of therapeutics against HBV and HDV. The whole picture of the complex HBV entry process became clear upon the follow-up studies over the years, including the recent resolution found for the NTCP structure. As one of the first authors of the 2012 eLife paper on NTCP identification, here, I (H. Y.) share our experience on the bumpy and exciting journey of receptor hunting, particularly on the photo-cross-linking study and some detailed descriptions of the “fishing” process and summarize the key factors for our successful receptor identification. This review may also provide helpful insights for identifying a protein target by peptide or protein baits through cross-linking and immunoprecipitation.

show abstract

“…Binding to cell receptors could be then detected with anti-MBP antibodies using flow cytometry analysis. By this approach, receptors responsible for HBV antigen surface binding and for cellular HBV entry were successfully detected (Park et al, 2000).…”

Section: Drug Targetingmentioning

confidence: 99%

Virus-like particles as drug delivery vectors

Zdanowicz¹,

Chroboczek

2016

Acta Biochim Pol

View full text Add to dashboard Cite

Virus-like particles (VLPs) assemble spontaneously during the viral cycle or in heterologous systems during expression of viral structural protein. Depending on the complexity of the VLPs, they can be obtained by expression in prokaryotic or eukaryotic expression system from the suitable recombinant vectors, or formed in cell-free conditions. Moreover, they can be built from proteins of a single virus, or can present the proteins or peptides derived from a virus or cell on a platform derived from any other single virus, thus forming chimeric VLPs. VLPs are best known for their immunogenic properties, but the versatility of VLPs allows a wide variety of applications. They are lately in the centre of investigations in vaccinology, drug delivery and gene therapy. This review focuses on utilization of VLPs for drug delivery.

show abstract

Detection of Cellular Receptors Specific for the Hepatitis B Virus preS Surface Protein on Cell Lines of Extrahepatic Origin

Cited by 6 publications

References 49 publications

Detection of surface asialoglycoprotein receptor expression in hepatic and extra-hepatic cells using a novel monoclonal antibody

Detection of surface asialoglycoprotein receptor expression in hepatic and extra-hepatic cells using a novel monoclonal antibody

Key Factors for “Fishing” NTCP as a Functional Receptor for HBV and HDV

Virus-like particles as drug delivery vectors

Contact Info

Product

Resources

About